Adherence in Adolescents and Children Treated on Quetiapine

AstraZeneca30 enrolled

Overview

Observational study aimed to describe the adherence in a population of adolescents and children treated on quetiapine from a first psychotic episode whose more important secondary objective is to identify possible predictive factors influencing the adherence to treatment with Quetiapine

Study Type

OBSERVATIONAL

Enrollment

Conditions

Psychosis

Eligibility

Sex: ALLMin age: 7 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least one psychotic symptom (delusions or hallucinations) before age 18. * Start of treatment in a maximum period of 2 years after the onset of first psychotic symptom * Written informed consent by parents or guardians and patients. Exclusion Criteria: * Pregnancy or lactancy * High risk of aggression or suicidal behaviour * Alcohol dependence

Outcomes

Primary Outcomes

Survival analysis of rate of adherence to treatment on quetiapine

Time frame: 6 months

Secondary Outcomes

Survival analysis of rate of adherence to treatment on quetiapine

Time frame: 12 months

Clinical and sociodemographic parameters (CGI-C, CGI-Suicidal, PANSS, HDRS, YMRS, SDQ, DAS, GAF, SUMD) possibly influencing adherence

Time frame: 0, 6, 12 months

Tolerability profile (UKU) possibly influencing adherence

Time frame: 0, 6, 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.